- Assistant professor of clinical immunology
- Research group leader - inborn errors of immunity affecting T cells and the thymus
- National clinical center for neonatal screening of inborn errors of immunity - primary recall physician
- University Hospital in Motol - 22q center coordinator
- 2nd Faculty of Medicine, Charles University - Deputy for undergraduate education of clical immunology and allergology
Primary immunodeficiencies
T cells
Thymus
Computational immunology
Registry
European Reference Networks
Curriculum Vitae – As. Prof. Adam Klocperk, MD, Ph.D.
(snapshot 17.3.2025)
Name: Adam Klocperk
Title: M.D., Ph.D., As. Prof.
Date of birth: 11.1.1989
Address: Na Petřinách 1896/31, Praha 6, 162 00, Czech Republic
Email: @email
Work email: @email
Telephone: +420 702 013 154
Higher education
|
Level |
Year |
Description |
|
Assistant professorship (As. Prof.) |
2024 |
Charles University Topic: T cells as key players in inborn errors of immunity |
|
Residency |
2014-2021 |
University Hospital in Motol |
|
Doctoral programme (Ph.D.) |
2014-2019 |
Charles University, 2nd Medical Faculty Programme: Immunology Topic: Adaptive immunity in patients with primary immunodeficiencies Supervisor: Prof. MUDr. Anna Šedivá, DSc. |
|
Master programme (M.D.) |
2008-2014 |
Charles University, 2nd Medical Faculty Programme: General medicine |
Recent work
|
Year |
Employer |
Position |
Reference contact |
|
2014-present |
Dpt. of Immunology, University Hospital Motol, Prague, CZ |
Clinical immunology consultant (primary immunodeficiency) |
Prof. MUDr. Anna Šedivá, CSc. (@email) |
|
2020-present |
Dpt. of Immunology, 2nd Faculty of Medicine, Charles University, CZ |
Deputy for undergraduate education |
Prof. MUDr. Jiřina Bartůňková, Dr.Sc. (@email) |
|
2024-present |
Dpt. of Immunology, University Hospital Motol, Prague, CZ |
Principal investigator, research group leader (T cell primary immunodeficiencies) |
Prof. MUDr. Anna Šedivá, CSc. (@email |
|
2018-2018 |
Center for Chronic Immunodeficiency, Freiburg, GER |
Visiting scientist (CVID, primary immunodeficiency) |
Prof. Dr. Med. Klaus Warnatz (@email) |
Published works
h-index: 15 Citations on WoS: 1164
Recent first or corresponding author (selected)
Klocperk A, et al. (2024). Neonatal screening of severe combined immunodeficiency (SCID) in the Czech Republic. Alergie, 2024(2), 85–89.
Vladyka O, et al. Profound T Lymphocyte and DNA Repair Defect Characterizes Schimke Immuno-Osseous Dysplasia. Journal of Clinical Immunology 2024;44:1–11.
Vladyka O, et al. Th1/interferon-γ bias in 22q11.2 deletion syndrome is driven by memory T cells and exacerbated by IL-7. Clin Immunol 2023:109793.
Klocperk A, et al. Distinct CD8 T Cell Populations with Differential Exhaustion Profiles Associate with Secondary Complications in Common Variable Immunodeficiency. J Clin Immunol 2022.
Smetanova J, et al. Accelerated Maturation, Exhaustion, and Senescence of T cells in 22q11.2 Deletion Syndrome. J Clin Immunol 2022;42:274–85.
Bloomfield, M & Klocperk A, et al. 2021. “Natural Course of Activated Phosphoinositide 3-Kinase Delta Syndrome in Childhood and Adolescence“. Front. Pediat. 2021, 9, 1-12
Klocperk A, et al. 2020. „Exhausted phenotype of follicular CD8 T cells in CVID.“ Journal of Allergy and Clinical Immunology 146(4):912-915.e13
Recent co-author (selected)
Kreins AY, et al. European Society of Immunodeficiencies guidelines for the management of patients with congenital athymia. J Allergy Clin Immunol 2024. https://doi.org/10.1016/j.jaci.2024.07.031.
Soomann M, et al. Variants in IGLL1 cause a broad phenotype from agammaglobulinemia to transient hypogammaglobulinemia. J Allergy Clin Immunol 2024;0. https://doi.org/10.1016/j.jaci.2024.08.002.
Howley E, et al. Impact of newborn screening for SCID on the management of congenital athymia. J Allergy Clin Immunol 2024;153:330–4.
Strohmeier V, et al. Interferon-Driven Immune Dysregulation in Common Variable Immunodeficiency-Associated Villous Atrophy and Norovirus Infection. J Clin Immunol 2022. https://doi.org/10.1007/s10875-022-01379-2.
Leiding J W, et al. Monogenic Early-Onset Lymphoproliferation and Autoimmunity: The Natural History of STAT3 GOF Syndrome. J. Allergy Clin. Immunol. (2022) doi:10.1016/j.jaci.2022.09.002
Manry J, et al. 2022. „The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies.“ Proc Natl Acad Sci U S A. 2022;119:e2200413119.
Bastard, P et al. 2021. „Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths “. Science Immunology 62(6):eabl4340
Awarded fellowships and grants (principal or co-recipient, selected)
2025-2026: Jeffrey Modell Foundation C.H.I.L.D.R.E.N. “22q ANTIC – Assessing patient Needs and Trajectories in Czechia”
2023-2026: AZV NU23-05-00097 “ThymIA: Thymic dysfunction and its role in Innate and Adaptive immunity”, co-recipient
2020-2023: AZV NU20-05-00282 “T-MAPs: High content mapping of surface molecules in normal and disturbed development of T lymphocytes, a search for diagnostic and therapeutic targets”, co-recipient, honorary award of the Czech minister of health
2020-2024: University Hospital in Motol Modern Therapies project “PIDLA: Web-based companion app for diagnosis of primary immunodeficiencies”, principal recipient
2018-2024: Charles University – University of Zurich bilateral support “Rare inborn erros of immunity - insight into pathogenesis and treatment options”
2018: ESID Medium-term Fellowship, awarded towards lab rotation at the AG Warnatz, Center for Chronic Immunodeficiency, Freiburg, Germany, project “Follicular cytotoxic T-cells in CVID”
Other recent awards (selected)
2020: European Society for Immunodeficiencies Junior Talent Award
2019: Alergie, best publication „First thymic transplant in the Czech Republic as a novel therapeutic option for patients with complete DiGeorge syndrome“